• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of medical intervention -- levels of care]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of care: norms and quality standards]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Leukotriene receptor antagonists in patients with asthma]
2009     The Swedish Council on Health Technology Assessment (SBU) [Leukocytapheresis in inflammatory bowel disease (primarily ulcerative colitis)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma): benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [LEG TEST. Multi centre testing of the Lively Legs program for promoting compliance with compression therapy and prescribed exercise in leg ulcer patients]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Left ventricular assist device (LVAD) as destination therapy]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lead extraction of pacemaker or implantable cardiac defibrillator leads using laser excimer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [LDL-Apheresis in familial hypercholesterolemia and hypertriglyceridemia]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Last trends in genetic therapy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2011     The Swedish Council on Health Technology Assessment (SBU) [Laser-induced interstitial thermal therapy for liver metastases]
2013     Haute Autorite de sante (HAS) [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Laser treatment for benign prostatic hyperplasia. Proposal of assessment indicators]
2009     The Swedish Council on Health Technology Assessment (SBU) [Laser technology for removal of caries]
2021     Andalusian Health Technology Assessment Area (AETSA) [Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Laser excimer in ophthalmology]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Laser angioplasty of coronary arteries]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Laronidase (Aldurazyme) for the treatment of mucopolysaccharidosis I]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Lapatinib or trastuzumab in combination with aromatase Inhibitors for hormone receptor positive/ErbB2-positive breast cancer]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lapatinib (Tyverb) for the treatment of metastatic breast cancer]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopy versus laparotomy in treatment of early stage endometrial cancer: a multi-centre cost-effectiveness study]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic vertical sleeve gastrectomy vs. laparoscopic Roux-en Y gastric bypass for the treatment of obesity]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic versus conventional surgery in colorectal cancer]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic surgery in kidney neoplasms]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery in colorectal cancer : quality of life, psychological impact and patient satisfaction]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Laparoscopic surgery for benign gynaecological disease]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery effectiveness and safety vs open surgery in colorectal cancer]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic peritoneal lavage for patients with perforated diverticulitis]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopic ileocolic resection versus infliximab treatment of recurrent distal ileitis in Crohn's disease: a randomized multicenter trial]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic hysterectomy and lymphadenectomy efficacy and safety in endometrial cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [Laparoscopic adjustable gastric banding for morbid obesity]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic (non robotic) radical prostatectomy versus open radical prostatectomy in localized prostate cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laminar air flow in the operating room to prevent hip and knee arthroplasty infections]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lacosamide in epilepsy]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Labour care in healthy women.Study of variability and systematic review]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [L-methionine in patients with neurogenic bladder disorders]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures - 1st Update 2010]
2009     National Evidence-based Healthcare Collaborating Agency (NECA) [Korean guidelines for the prophylactic use of white blood growth factors]
2006     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Knee arthrosis patient management in primary care clinical practice guideline (CPG)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Kinanthropometric nutritional assessment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ki-67 proliferative index in patients with early breast cancer]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Key factors in Electronic Clinical Guides: Breast Cancer]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in central nervous system tumors]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet for refractory epilepsy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogue diet for advanced chronic kidney failure]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogs in association with high protein diet in chronic kidney failure]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Judicious use of 14 laboratory tests]
2009     Committee for New Health Technology Assessment (CNHTA) [JAK2 gene exon 12 mutation analysis]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-65]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ivermectin for COVID-19]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [homozygous for the F508del mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [heterozygous for F508del and MF mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, gating mutation, heterozygous) – Benefit assessment according to §35a]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, RF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, other/unknown mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, MF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]